Company Profile
Sana Biotechnology Stock Price, News & Analysis
- Ticker:
- SANA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.41 USD (-2.85%)
Close
Last updated: August 6, 2026
902M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, SANA closed down 2.85% at $3.41. No new same-company headline was identified in the current news window.
Company overview
Engineered Cell Therapies
Sana Biotechnology develops engineered cells intended to repair or replace damaged biology while overcoming immune rejection. Its platform spans ex vivo cell replacement and in vivo delivery technologies.
SC451 Islet-Cell Therapy
SC451 is a gene-modified, stem-cell-derived pancreatic islet-cell candidate designed to restore insulin production in people with type 1 diabetes without chronic immunosuppression. Sana is advancing the program in collaboration with Mayo Clinic.
UP421 Clinical Validation
UP421 is a hypoimmune-modified primary islet-cell therapy being evaluated in an investigator-sponsored study without immunosuppression. Survival and insulin-producing function observed after transplantation provide human validation for the immune-evasion technology used in SC451.
SG293 In Vivo CAR-T
SG293 uses a CD8-targeted fusosome to deliver genetic material that creates CD19-directed CAR-T cells inside the body. Sana plans to begin in non-Hodgkin lymphoma before potentially expanding into B-cell-mediated autoimmune diseases.
SG227 Multiple-Myeloma Program
SG227 applies the same in vivo delivery approach to a BCMA-directed CAR for multiple myeloma. Its clinical entry is contingent on the initial safety and efficacy profile of SG293.
Future catalysts
IND submission and initiation of a Phase 1 study of SC451 later in 2026.
Initiation of a clinical study of SG227 as early as mid-2027.
Recent news
- 01
- 02
- 03
Sana Biotechnology to Present at June 2026 Investor Conferences
Source: Sana Biotechnology
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Sana Biotechnology (SANA)?
Sana Biotechnology (SANA) most recently closed at 3.41 USD, a -2.85% move versus the previous session.
What is the market cap of Sana Biotechnology (SANA)?
Sana Biotechnology currently has a market capitalization of 902M USD on BioPharmSignal.
What does Sana Biotechnology do?
Engineered Cell Therapies Sana Biotechnology develops engineered cells intended to repair or replace damaged biology while overcoming immune rejection. Its platform spans ex vivo cell replacement and in vivo delivery technologies. SC451 Islet-Cell Therapy SC451 is a gene-modified, stem-cell-derived pancreatic islet-cell candidate designed to restore insulin...
On which exchange is SANA stock listed?
Sana Biotechnology (SANA) is associated with NASDAQ, United States, Biopharma.
What is CAR-T?
SG293 In Vivo CAR-T SG293 uses a CD8-targeted fusosome to deliver genetic material that creates CD19-directed CAR-T cells inside the body.
Which conditions is Sana Biotechnology targeting with CAR-T?
Sana Biotechnology is associated with diabetes, genetic disease based on its company overview and current catalyst commentary.
How does Sana Biotechnology describe recent progress with CAR-T?
IND submission and initiation of a Phase 1 study of SC451 later in 2026. Initiation of a clinical study of SG227 as early as mid-2027.
What is Engineered?
Engineered Cell Therapies Sana Biotechnology develops engineered cells intended to repair or replace damaged biology while overcoming immune rejection.